Servicio de Cardiología, Unidad de Insuficiencia Cardíaca, Hipertensión Pulmonar y Trasplante Cardíaco, H.U. 12 de Octubre, Red de Investigación Cooperativa del Ministerio de Sanidad y Consumo de España, Madrid, Spain.
Arch Bronconeumol. 2011 Jan;47(1):10-6. doi: 10.1016/j.arbres.2010.07.013. Epub 2010 Dec 10.
Ergospirometry objectively quantifies exercise capacity. Up until now, the response to exercise evaluated by ergospirometry in patients with pulmonary arterial hypertension has only been described in recently diagnosed.patients. Our aim is to describe the response to exercise in patients with severe pulmonary arterial hypertension under specific treatment and define which parameters determine their exercise capacity.
A cross-sectional study was performed on 80 patients, 57 women, aged 45 (14), with severe pulmonary arterial hypertension (48 idiopathic, 14 related to toxic rapeseed oil, 13 to connective tissue disease, 5 to human immunodeficiency virus), mean pulmonary pressure at diagnosis 61(15)mmHg and after 49(33) months under treatment since diagnosis. Biomarkers were measured and echocardiography and ergospirometry were performed the same day.
Our patients, under specific treatment, showed the typical behaviour of patients with pulmonary arterial hypertension with less limitation of both aerobic capacity and ventilatory efficiency. Being male (p=0.004), high ventilatory equivalent for carbon dioxide at anaerobic threshold (p<0.001) or biomarkers (p=0.006) were the strongest predictors of impaired peak oxygen uptake in multivariate analysis, whereas for an impaired percentage achieved of predicted value were right ventricle diastolic diameter (p<0.001), months of treatment (p=0.01) and high ventilatory equivalent for CO(2) (p<0.001).
In pulmonary arterial hypertension, right ventricle dysfunction (expressed by its dilation or high NTproBNP) and impaired ventilatory inefficiency as well as being male or a short time under treatment can be considered as determining factors of impaired exercise capacity.
运动心肺功能测定可客观地量化运动能力。迄今为止,运动心肺功能测定评估肺动脉高压患者运动反应的研究仅在近期诊断的患者中进行了描述。我们的目的是描述在特定治疗下严重肺动脉高压患者的运动反应,并确定哪些参数决定其运动能力。
对 80 名患者(57 名女性,年龄 45[14]岁)进行了横断面研究,这些患者均患有严重的肺动脉高压(48 例特发性肺动脉高压,14 例与毒油菜籽油有关,13 例与结缔组织病有关,5 例与人类免疫缺陷病毒有关),诊断时平均肺动脉压为 61(15)mmHg,自诊断后 49(33)个月开始接受治疗。当天同时进行了生物标志物检测、超声心动图和运动心肺功能测定。
在特定治疗下,我们的患者表现出典型的肺动脉高压患者行为,有氧能力和通气效率受限较少。在多变量分析中,男性(p=0.004)、无氧阈时的二氧化碳通气当量高(p<0.001)或生物标志物高(p=0.006)是峰值摄氧量受损的最强预测因子,而对于预测值百分比的受损,右心室舒张直径(p<0.001)、治疗时间(p=0.01)和高二氧化碳通气当量(p<0.001)是主要决定因素。
在肺动脉高压中,右心室功能障碍(表现为扩张或高 NTproBNP)和通气效率受损,以及男性或治疗时间较短,可被视为运动能力受损的决定因素。